Literature DB >> 21563612

Time trends in the epidemiology of microbial infections at a tertiary care center in west India over last 5 years.

Atul K Patel1, Ketan K Patel, Kamlesh R Patel, Sanjiv Shah, Pratibha Dileep.   

Abstract

INTRODUCTION: Microbiological surveillance data is of crucial importance in appropriate management of patients with infectious diseases. The current study was conducted to study the microbiological surveillance data along with antibiotic sensitivity patterns for isolates collected at a single tertiary care center from Western India over last four years and to analyze the change in the patterns of nosocomial infections seen over the last four year period.
DESIGN: Retrospective study. Culture reports data were retrospectively collected from microbiology department of Sterling hospital Ahmedabad. Isolates from clinical specimen from blood cultures, surgical site swabs, abdominal drain fluid, urine samples and bronchoscopy samples were analysed in present study. Isolates from respiratory secretions includind endotracheal, tracheostomy and sputums were excluded from analysis, Frequency of different organisms which were isolated as well the sensitivity patterns to major antibiotics were recorded.
RESULTS: Among the blood isolates there was a clear trend regarding the emergence of gram positive organisms with Staphylococcus being the most common isolate from 149 blood culture specimens in the period 2008-09 (27.4%). Majority (> 85%) of gram negative isolates causing blood stream infections were sensitive to Amikacin, Cefoperazone-Sulbactam, Piperaciln-Tazobactam, Meropenem and Colistin. On the other hand, sensitivity of gram negative isolates from other sites to these antibiotics was much more variable. Incidence of candidemia went down from 20.3% to 13.4% in 2005-6 and in 2008-09 respectively.
CONCLUSION: Staphylococcus aureus has emerged as the dominant pathogen causing the blood stream infections in last two years. Piperacilin-tazobactum, cefaperazone-sulbactum or meropenem may be appropriate as empiric antibiotic choice for gram negative blood stream infections along with Amikacin for patients with serious infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21563612

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  6 in total

1.  SCC mec typing and antimicrobial resistance of methicillin-resistant Staphylococcus aureus (MRSA) from pigs of Northeast India.

Authors:  S Rajkhowa; D K Sarma; S R Pegu
Journal:  Vet Res Commun       Date:  2016-07-23       Impact factor: 2.459

2.  Epidemiological study of prevalence, determinants, and outcomes of infections in medical ICU at a tertiary care hospital in India.

Authors:  Rajesh Ghanshani; Rajeev Gupta; Bhagwan Swarup Gupta; Sushil Kalra; Raghubir Singh Khedar; Smita Sood
Journal:  Lung India       Date:  2015 Sep-Oct

3.  Is methicillin-resistant Staphylococcus Aureus infection associated with higher mortality and morbidity in hospitalized patients? A cohort study of 551 patients from South Western India.

Authors:  Aparajita Chatterjee; Shipra Rai; Vasudeva Guddattu; Chiranjay Mukhopadhyay; Kavitha Saravu
Journal:  Risk Manag Healthc Policy       Date:  2018-12-03

4.  Comparison of PCR and phenotypic methods for the detection of methicillin resistant Staphylococcus aureus.

Authors:  Anitha Madhavan; Arun Sachu; Anukumar Balakrishnan; Anu Vasudevan; Sobha Balakrishnan; Jayalakshmi Vasudevapanicker
Journal:  Iran J Microbiol       Date:  2021-02

5.  Prevalence of S. aureus and/or MRSA from seafood products from Indian seafood products.

Authors:  Gopalan Krishnan Sivaraman; Sobin Sonu Gupta; S Visnuvinayagam; T Muthulakshmi; Ravikrishnan Elangovan; Vivekanandan Perumal; Ganesh Balasubramanium; Tushar Lodha; Amit Yadav
Journal:  BMC Microbiol       Date:  2022-10-01       Impact factor: 4.465

6.  Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern.

Authors: 
Journal:  Indian J Med Res       Date:  2013-02       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.